Search

Prolease-r-hFSH

It provides patients with long term therapeutic benefit from a single administration rather than multiple injections.

INGN 225

INGN 225 is currently in Phase 1/2 trials in patients with small cell lung cancer and breast cancer. … INGN 225 is a therapeutic consisting of a cancer patient's own immune cells treated with an adenovector carrying the human p53 gene, Ad-p53.

Epoetin delta

Epoetin Delta is an ingredient in the EMA-withdrawn product Dynepo.

BL-1020

It is being developed by BioLineRx (BioLine).

Zilebesiran

Zilebesiran is under investigation in clinical trial NCT06272487 (Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care

DG041

DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2. … It block the formation of blood clots mediated through inflammation in atherosclerotic plaques but without increasing bleeding risk.

Kojic acid

CY301

CY301 (Simplivir) is an investigational gene silencing compound developed by CytoGenix for the treatment of HSV.

Otelixizumab

Tolerx is developing otelixizumab to treat patients with type 1 diabetes, psoriasis and other autoimmune diseases such as rheumatoid arthritis. … Otelixizumab is believed to inhibit the function of autoreactive T cells, which are important in propagating autoimmune diseases, while inducing regulatory T cell pathways that promote immunological tolerance and

AVR118

of cancers); for its ability to stimulate the immune system to attack tumor cells (especially those cancer cells that have been damaged by chemotherapeutic agents) and for its ability to treat cachexia … papilloma virus and to dampen aberrant autoimmune-type inflammatory responses.